The Role of IL-17 Cytokines in Psoriasis
Megan Mosca,Julie Hong,Edward Hadeler,Marwa Hakimi,Wilson Liao,Tina Bhutani
DOI: https://doi.org/10.2147/ITT.S240891
2022-05-25
ImmunoTargets and Therapy
Abstract:Megan Mosca, Julie Hong, Edward Hadeler, Marwa Hakimi, Wilson Liao, Tina Bhutani Psoriasis and Skin Treatment Center, Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Correspondence: Megan Mosca Psoriasis and Skin Treatment Center, Department of Dermatology, University of California San Francisco, 515 Spruce Street, San Francisco, CA, 94118, USA Email Psoriasis is a chronic inflammatory skin condition associated with immune dysregulation. The immunologic cascade mediated by the interleukin (IL)-17 pathway plays a critically important role in the pathogenesis of psoriasis. The IL-17 effectors (IL-17A, IL-17C, IL-17E, and IL17F) act on keratinocytes, endothelial cells, and immune cells to stimulate epidermal hyperplasia and the pro-inflammatory feed-forward cycle seen within plaque psoriasis. The IL-17 pathway is also hypothesized to modulate the inflammatory responses linking comorbid systemic diseases with psoriasis. Furthermore, the robust clinical response seen with current and emerging therapies targeting IL-17 emphasizes the importance of the IL-17 cytokines in the pathogenesis of psoriasis. Keywords: IL-17, plaque psoriasis, pathogenesis, biologics, immune pathway Psoriasis is a chronic immune-mediated, inflammatory skin condition, which affects approximately 7.4 million adults in the United States. 1 It is characterized by well-demarcated, erythematous, scaly plaques and involves increased keratinocyte proliferation and pro-inflammatory cytokines. 2 While the pathogenesis is complex and not fully elucidated, psoriasis is thought to result from a combination of immunologic, genetic, and environmental factors. 2 Upregulation and activation of immune pathways play a crucial role in the immunologic mechanism of psoriasis. The interleukin-23/ T helper 17 (IL-23/Th17) mediated activation of IL-17 is recognized as the dominant pathway and plays a critical role in the pathogenesis of psoriasis. 3,4 The IL-17 signaling pathway and its products are key contributors to psoriatic inflammation. Given its pathogenic role, this pathway has become a therapeutic target for several psoriasis treatments. Currently, three biologic therapies targeting the IL-17 pathway are FDA approved for the treatment of moderate to severe plaque psoriasis: ixekizumab, secukinumab, and brodalumab. Additionally, current research is underway to evaluate the efficacy of two new biologic treatments, bimekizumab, an inhibitor of IL-17A and IL-17-F, and netakimab, an inhibitor of IL-17A. 5,6 An update on the contribution of the IL-17 cytokines in psoriasis pathogenesis and its involvement in mediating comorbid conditions is discussed below. Additionally, we highlight the pertinent Phase III efficacy and safety data of IL-17 inhibitors, emphasizing recent studies and novel therapeutic agents. The IL-17 family consists of six isoforms (IL-17A-IL-17F). 7 IL-17A and IL-17F are primarily involved in the pathogenesis of psoriasis, but IL-17C and IL-17E are also implicated in the disease state. Furthermore, the expression of these four cytokines is increased within psoriatic skin lesions, supporting their role in psoriasis. 8–10 Protein levels of IL-17A, IL-17C, and IL-17F in lesional psoriatic skin are significantly increased by 6.7-fold, 4.1-fold, and 8-fold, respectively, when compared to nonlesional skin. 9 IL-17A and IL-17F share the most homologous structure, sharing approximately 50% of their sequence identity. 11 IL-17A exists in two forms, as a homodimer and a heterodimer in combination with IL-17F (IL-17A/ IL-17F). Additionally, IL-17A homodimer, IL-17F homodimer, and IL-17A/IL-17F heterodimer all bind to the same heterodimeric receptor, IL-17R, which is comprised of IL-17RA and IL-17RC. 12 However, the IL-17A homodimer is the most biologically active isomer with downstream gene activation approximately 10–30 fold stronger when compared to activation by the IL-17F homodimer. 12,13 Under physiologic conditions, the IL-17 pathway contributes to defenses against extracellular fungi and bacteria. In particular, IL-17A bridges the gap between the innate and adaptive immune systems. Through chemokine expression and gradients, IL-17A initiates immune responses at mucosal surfaces, resulting in the recruitment of neutrophils to the tissue. 14 Neutrophils, in turn, secrete IL-17, which amplifies the response and leads to the recruitment of additional neutrophils. 15 However, the IL-17 pathway also plays a significant role in the origin and the feed-forward inflammatory cycle of psoriasis. When an individual with a genetic predisposition experiences a trigger for psoriasis, the adaptive immune system initiates an immunologic cascade. 2 Myeloid dendritic c -Abstract Truncated-